Susan R. Vishneski, MD
San Diego—Researchers at Wake Forest School of Medicine have identified a series of risk factors for residual neuromuscular blockade after rocuronium administration in pediatric patients.
Their study concluded that a gap of less than 35 minutes between the final dose of rocuronium and neostigmine administration, as well as a cumulative rocuronium dose greater than 0.51 mg/kg per hour, were significantly associated with the need for additional reversal. The analysis